知镜 Cognispect · 医学文献与研究工作台

Estimation of Urinary Marinobufagenin in Stable Chronic Kidney Disease Patients: A Hospital-based Cross-sectional Study.

Verma N, Sachan A, Patel ML, Sachan R, Ali W.
Annals of African medicine · 2026-09-24 · PMID 42784430

文献摘要

Background Chronic kidney disease (CKD) is associated with accumulation of endogenous cardiotonic steroids, including marinobufagenin (MBG), a bufadienolide that inhibits Na+/K+-ATPase and promotes renal and cardiac fibrosis. Urinary MBG (uMBG) excretion reflects glomerular filtration and may decline as renal function deteriorates, yet data from Indian populations are lacking. Objectives To estimate uMBG levels in stable CKD patients (kidney disease improving global outcomes stages 2-4), to correlate these levels with markers of renal function and CKD severity, and to assess the diagnostic utility of uMBG as a biomarker. Methods A hospital-based cross-sectional study was conducted in department of medicine King George's Medical University, Lucknow over a period of 1 year. Seventy stable CKD patients (stages 2-4) and 25 age-and sex-matched healthy controls were enrolled. uMBG was estimated by competitive enzyme-linked immunosorbent assay method. Results uMBG was significantly lower in CKD patients compared to controls (median 6.85 [interquartile range 4.95-8.59] vs. 11.78 [10.61-12.3] pg/mL; P Conclusion uMBG is significantly reduced in stable CKD and declines progressively with advancing disease stage, mirroring the decline in glomerular filtration rate. uMBG has the ability to be a novel, stage-sensitive biomarker for CKD due to its excellent diagnostic accuracy (AUC 0.914).

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。